Baricitinib

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Baricitinib

Examples of brand names: Olumiant [EU/DE]

ATC code: L04AF02

Main use (for orientation): Inflammatory diseases

Documented research summary

No direct finding for the pair. CBD CYP3A inhibition alone is not a reliable explanation for baricitinib accumulation.

Uncertainties and limitations

In vitro transporter findings do not allow a quantified clinical cannabinoid prediction.

Do not treat therapeutic immunosuppression as evidence of additional cannabinoid harm.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Drug context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Insufficient pair-specific data

Mechanism / drug context: Baricitinib: predominantly renal excretion; OAT3, little CYP metabolism.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Oral Olumiant/baricitinib, US label dated 25 September 2026; indications, sections 7 and 12 read. JAK inhibitor, predominantly excreted unchanged renally; only approximately 6% as metabolites, secondary CYP3A4 pathway. OAT3/P-gp/BCRP/MATE2-K substrate. Ketoconazole without a pharmacokinetic effect, fluconazole/rifampicin without clinically relevant pharmacokinetic changes; probenecid as a strong OAT3 inhibitor increases AUC approximately 2-fold. Not a simple CYP3A4 class-effect model.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [RLABEL_D0030]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: OLUMIANT (BARICITINIB) TABLET, FILM COATED [ELI LILLY AND COMPANY] [RLABEL_D0030]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[RLABEL_D0030] OLUMIANT (BARICITINIB) TABLET, FILM COATED [ELI LILLY AND COMPANY]

Original source / bibliographic reference

Authors: Regulatory product information; respective marketing authorisation holder

Year: 2026

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility